UNSPSC 51401560: Adinazolam mesilate or mesylate

This classification denotes a benzodiazepine with the molecular formula C19H18CLN5.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NT8S62A727. The term adinazolam mesilate is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule adinazolam mesylate under HS 29339940. As of Q4 2014, ADINAZOLAM MESYLATE remains US FDA's Preferred Term for this commodity. Adinazolam mesylate bears US NLM identifiers UMLS ID C0167214 and NCI Concept Code C76532.

SMILES: CN(C)CC1NNC2N1-C3CCC(CC3C(=NC2)C4CCCCC4)CL.CS(=O)(=O)O.

UNSPSC 51401560 Adinazolam mesilate or mesylate is a Commodity code that captures state and local government procurement of benzodiazepine pharmaceuticals and related therapeutic agents for community health, emergency response, and public health programs. State and local buyers under this code include county health departments, state health and human services agencies, and cooperative purchasing alliances serving multi-state government consortia. The scope of work spans acquisition of finished pharmaceutical products for inventory replenishment, emergency preparedness, and substance-abuse intervention programs, with vendors required to meet FDA compliance, cGMP certification, Drug Supply Chain Security Act (DSCSA) standards, and established insurance and workplace-verification requirements typical of pharmaceutical distribution to public entities.

Recent activity shows three representative solicitations across Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the county community health building, response due July 26, 2026, under a two-year initial term with one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling state interest in alternative distribution models outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products with responses due March 26, 2026, requiring vendors to supply through three authorized wholesalers and comply with 75-percent price-competitiveness weighting. Geographic activity concentrates in the Southeast (Florida), South (Texas), and Upper Midwest (Minnesota and participating MMCAP states including Oregon), with procurement driven by public health emergency response, state employee benefit programs, and cooperative purchasing leverage across multiple jurisdictions.